CD1D and neoplasm: Here, we used an in vivo A375-CD1d human melanoma xenograft NSG mouse model, wherein A375-CD1d tumor cells were subcutaneously inoculated into the left side of the experimental NSG mice on day 0, followed by the tumor-localized injection of αGC and the intravenous injection of PBMC-iNKT-FG cells on day 3 (Figure 5B).